




RealRate

PHARMACEUTICAL 2022

Sarepta Therapeutics Inc
Rank 347 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 78% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,604,099
Cost of Goods Sold	0
Intangible Assets	14,239
Liabilities, Current	452,733
Liabilities, Non-Current	626,756
Other Assets	338,480
Other Compr. Net Income	-23
Other Expenses	107,587
Other Liabilities	1,140,476
Other Net Income	40,762
Other Revenues	701,887
Property and Equipment	191,156
Research and Development	771,182
Selling, General and Administrative Expense	282,660

Output Variable	Value in 1000 USD
Assets	3,147,974
Liabilities	2,219,965
Expenses	1,161,429
Revenues	701,887
Stockholders Equity	928,009
Net Income	-418,780
Comprehensive Net Income	-418,792
BaseVar	3,636,020
ECR before LimitedLiability	60%
Economic Capital Ratio	197%